August 1, 2025Journal of Investigative Medicine High Impact Case ReportsOpen Access

Central Nervous System Toxoplasmosis in the Setting of Mycophenolate Mofetil Monotherapy for Autoimmune Hepatitis

View Full Paper

Ask AI

Bookmark

Authors

SKSathish KrishnanThiruvalluvar University VRVijaya Sivalingam RamalingamNortheast Georgia Medical Center ANAnam NaumaanCommunity Health Network

Discussion

Member takes

Implication

Case report highlights CNS toxoplasmosis in a patient with autoimmune hepatitis on mycophenolate mofetil, suggesting increased risk for opportunistic infections.

Key Points

CNS toxoplasmosis occurred in a 68-year-old with autoimmune hepatitis, indicating serious risks from immunosuppressive therapy.
Toxoplasma IgG levels were elevated, confirming reactivation of the parasite rather than a new infection.
A stereotactic biopsy revealed Toxoplasma gondii present in necrotic brain tissue, reinforcing the need for thorough diagnosis.
Discontinuation of mycophenolate mofetil led to clinical improvement, pointing to the risks of chronic immunosuppression.

Cite This Study

Krishnan et al. (2025) studied this question.

synapsesocial.com/papers/68af55d8ad7bf08b1eadc80d https://doi.org/10.1177/23247096251366928

View Full Paper

Ask AI

Bookmark

Implication

Case report highlights CNS toxoplasmosis in a patient with autoimmune hepatitis on mycophenolate mofetil, suggesting increased risk for opportunistic infections.

Central Nervous System Toxoplasmosis in the Setting of Mycophenolate Mofetil Monotherapy for Autoimmune Hepatitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Central Nervous System Toxoplasmosis in the Setting of Mycophenolate Mofetil Monotherapy for Autoimmune Hepatitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider